Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.23 - $3.45
Previous CloseN/A
Volume148.24K
Average Volume (3M)1.54M
Market Cap
$433.40M
Enterprise Value$463.52M
Total Cash (Recent Filing)-$50.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding283,265,720
10 Day Avg. Volume1,960,785
30 Day Avg. Volume1,535,334
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)749.69
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-124.20
Enterprise Value/Ebitda-3.06
Forecast
1Y Price Target
$5.00Price Target Upside226.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Erasca News
PremiumCompany Announcements
Erasca, Inc. Reports 2024 Financial and Strategic Progress
PremiumCompany Announcements
Erasca Highlights Strategic Focus at Healthcare Conference---
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceNaporafenib has performed well in melanoma with a competitive clinical profile, showing a higher overall response rate compared to standard chemotherapy and MEK inhibitors.
InnovationERAS-0015 and ERAS-4001 differentiate themselves from existing RAS inhibitors by targeting broader RAS mutations and employing novel mechanisms of action.
Regulatory ProgressERAS has received alignment on its approval strategy from both the US and EU regulatory agencies for a tissue-specific indication in melanoma.
Bears Say
Clinical ChallengesDurable responses were only seen in melanoma patients, with no responses in CRC and PDAC patients, leading to a shift away from a tissue-agnostic approach.
Development TimelineIt will take time for clinical data to be generated for ERAS-0015 and ERAS-4001.
Efficacy LimitationsEfficacy in non-melanoma tumor types was limited, with a 23% response rate, which was anticipated given the complex MAPK feedback across different tissue types.
---
Ownership Overview
22.57% Insiders
10.56% Mutual Funds
<0.01% Other Institutional Investors
57.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.23 and its highest was $3.45 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $433.40M.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Mar 20, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.125 by $0.015.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.13.
How many shares outstanding does Erasca have?
Erasca has 283,265,720 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.125. Following the earnings report the stock price went up 3.378%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
---
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (226.80% Upside)
$5.00 (226.80% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 67.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.83%
12-Months-Change
Fundamentals
Return on Equity
-43.68%
Trailing 12-Months
Asset Growth
27.13%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc. (ERAS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oncology therapies. The company aims to eradicate cancer by targeting biological drivers of the disease using precision medicine approaches. Erasca is working on a pipeline of small molecule drugs designed to inhibit oncogenic signaling pathways and address unmet needs in cancer treatment.
---
ERAS Stock 12 Month Forecast
Average Price Target
$5.00
▲(226.80% Upside)
Technical Analysis
Fate Therapeutics
―
Blueprint Medicines
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering ERAS
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-18.26%
reiterated a buy rating 7 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -18.26% per trade.
---